GLP1R and Alzheimer disease: AD rodent models chronically treated with the GLP-1 analog Val(8)glucagon-like peptide-1 caused modulation of neurotransmitter release, synaptic transmission (LTP) formation, and restoration of synaptic plasticity, as well as preventing impairment in the learning of new spatial tasks (328–330).